Regulation of DNA Synthesis by the Higher-Order Chromatin Structure

Kunnev, Dimiter; Gospodinov, Anastas; Russev, George; Anachkova, Boyka
May 2000
DNA & Cell Biology;May2000, Vol. 19 Issue 5, p283
Academic Journal
Mouse erythroleukemia cells were treated with the topoisomerase II poison VP-16, the intrastrand crosslinking agent cis-DDP, and the ribonucleotide reductase inhibitor hydroxyurea. In all cases, the rate of DNA synthesis decreased as a result of the treatment. To study the mechanism of inhibition of DNA chain elongation, we determined DNA synthesis in a cell-free replication system containing isolated nuclei and cytoplasmic extracts. The rate of DNA synthesis in the reactions containing nuclei isolated from untreated cells and extracts from cells treated with the three drugs were slightly reduced and did not show significant differences between the drugs. In the systems containing nuclei from cells treated with cis-DDP, DNA synthesis was again slightly inhibited; synthesis in nuclei treated with hydroxyurea was enhanced, and synthesis in the systems containing nuclei from cells treated with VP-16 was significantly reduced. DNA synthesis was reduced to the same extent in a system containing nuclei isolated from untreated cells that had been briefly sonicated to introduce a limited number of double-strand breaks in the DNA. As VP-16 and sonication mediate changes in chromatin topology, these results suggest that, along with the trans-acting signal transduction pathways, there is a topologic mechanism for regulation of DNA synthesis in the S phase of the cell cycle.


Related Articles

  • DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates. Mondal, Neelima; Parvin, Jeffrey D. // Nature;9/27/2001, Vol. 413 Issue 6854, p435 

    Reports that the DNA topoisomerase IIalpha is required for RNA polymerase II transcription on chromatin templates. Chromatin-dependent coactivation; Association of the DNA topoisomerase with the holo-pol; Transcription on chromatin templates resulted in the accumulation of superhelical tension.

  • Chromatin-remodeling factor CHRAC contains the ATPases ISWI and topoisomerase II. Varga-Weisz, Patrick D.; Wilm, Matthias // Nature;8/7/1997, Vol. 388 Issue 6642, p598 

    Reports that chromatin-remodeling factor or chromatin-accessibility complex (CHRAC) contains the ATPases ISWI and topoisomerase II. Nucleosome-remodeling factor (NURF) as isolated from Drosophila embryo extracts; How CHRAC functions; The use of mass spectrometry; What the presence of ISWI in...

  • PIASy mediates SUMO-2 conjugation of Topoisomerase-II on mitotic chromosomes. Azuma, Yoshiaki; Arnaoutov, Alexei; Anan, Tadashi; Dasso, Mary // EMBO Journal;6/15/2005, Vol. 24 Issue 12, p2172 

    Here we show that the PIASy protein is specifically required for mitotic modification of Topoisomerase-II by SUMO-2 conjugation in Xenopus egg extracts. PIASy was unique among the PIAS family members in its capacity to bind mitotic chromosomes and recruit Ubc9 onto chromatin. These properties...

  • Topoisomerase II—DNA complexes trapped by ICRF-193 perturb chromatin structure. Germe, Thomas; Hyrien, Olivier // EMBO Reports;Aug2005, Vol. 6 Issue 8, p729 

    DNA topoisomerase II (topo II) is involved in unlinking replicating DNA and organizing mitotic chromosomes. Topo II is the target of many antitumour drugs. Topo II inhibition results in extensive catenation of newly replicated DNA and may potentially perturb chromatin assembly. Here, we show...

  • Displacement of D1, HP1 and topoisomerase II from satellite heterochromatin by a specific polyamide. Blattes, Roxane; Monod, Caroline; Susbielle, Guillaume; Cuvier, Olivier; Jian-hong Wu; Hsieh, Tao-shih; Laemmli, Ulrich K; Käs, Emmanuel // EMBO Journal;6/7/2006, Vol. 25 Issue 11, p2397 

    The functions of DNA satellites of centric heterochromatin are difficult to assess with classical molecular biology tools. Using a chemical approach, we demonstrate that synthetic polyamides that specifically target AT-rich satellite repeats of Drosophila melanogaster can be used to study the...

  • Topoisomerase II Hypersensitive Sites in the 5"-Terminal Region of Human Dystrophin Gene. Bystritskii, A. A.; Hancock, R.; Razin, S. V.; Yarovaya, O. V. // Doklady Biochemistry & Biophysics;May/Jun2001, Vol. 378 Issue 1-6, p198 

    Presents information on a study which investigated topoisomerase II hypersensitive sites in the 5'-terminal region of the human dystrophin gene. Length of the human dystrophin gene located in the X-chromosome; Characteristics of the human dystrophin gene; Implementation of the project aimed at...

  • Topoisomerase II plays a role in dosage compensation in Drosophila. Cugusi, Simona; Ramos, Edward; Ling, Huiping; Yokoyama, Ruth; Luk, Kevin M.; Lucchesi, John C. // Transcription (2154-1264);Nov2013, Vol. 5, p1 

    In Drosophila, dosage compensation is mediated by the MSL complex, which binds numerous sites on the X chromosome in males and enhances the transcriptional rate of a substantial number of X-linked genes. We have determined that topoisomerase II (Topo II) is enriched on dosage compensated genes,...

  • In vivo modeling of polysumoylation uncovers targeting of Topoisomerase II to the nucleolus via optimal level of SUMO modification. Takahashi, Yoshimitsu; Strunnikov, Alexander // Chromosoma;Mar2008, Vol. 117 Issue 2, p189 

    Conjugation of SUMO to target proteins is an essential eukaryotic regulatory pathway. Multiple potential SUMO substrates were identified among nuclear and chromatin proteins by proteomic approaches. However, the functional roles of SUMO-modified pools of individual proteins remain largely...

  • ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia. Canaani, E.; Nakamura, T.; Rozovskaia, T.; Smith, S. T.; Mori, T.; Croce, C. M.; Mazo, A. // British Journal of Cancer;2/23/2004, Vol. 90 Issue 4, p756 

    Rearrangements of the ALL-1/MLL1 gene underlie the majority of infant acute leukaemias, as well as of therapy-related leukaemias developing in cancer patients treated with inhibitors of topoisomerase II, such as VP16 and doxorubicin. The rearrangements fuse ALL-1 to any of >50 partner genes or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics